Caroline Robert

List of Publications by Citations

472 papers	91,634 citations	115 h-index	301 g-index
536 ext. papers	110,126 ext. citations	9.5 avg, IF	7.77 L-index

#	Paper	IF	Citations
472	Improved survival with ipilimumab in patients with metastatic melanoma. *New England Journal of Medicine*, **2010**, 363, 711-23	59.2	10591
471	Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *New England Journal of Medicine*, **2011**, 364, 2507-16	59.2	5851
470	PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature*, **2014**, 515, 568-71	50.4	4014
469	Nivolumab in previously untreated melanoma without BRAF mutation. *New England Journal of Medicine*, **2015**, 372, 320-30	59.2	3809
468	Pembrolizumab versus Ipilimumab in Advanced Melanoma. *New England Journal of Medicine*, **2015**, 372, 2521-32	59.2	3792
467	Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *New England Journal of Medicine*, **2011**, 364, 2517-26	59.2	3396
466	Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. *New England Journal of Medicine*, **2013**, 369, 134-44	59.2	2661
465	Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. *New England Journal of Medicine*, **2015**, 372, 2006-17	59.2	2001
464	Improved overall survival in melanoma with combined dabrafenib and trametinib. *New England Journal of Medicine*, **2015**, 372, 30-9	59.2	1723
463	Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. *Science*, **2015**, 350, 1079-84	33.3	1689
462	Improved survival with MEK inhibition in BRAF-mutated melanoma. *New England Journal of Medicine*, **2012**, 367, 107-14	59.2	1634
461	Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. *Journal of Clinical Oncology*, **2015**, 33, 1889-94	2.2	1425
460	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. *Lancet, The*, **2014**, 384, 1109-17	40	1340
459	Immune-related adverse events with immune checkpoint blockade: a comprehensive review. *European Journal of Cancer*, **2016**, 54, 139-148	7.5	1239
458	Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. *New England Journal of Medicine*, **2014**, 371, 1877-88	59.2	1195
457	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. *Lancet Oncology, The*, **2015**, 16, 908-18	21.7	1151
456	Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, **2017**, 28, iv119-iv142	10.3	1100

455	Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group **2017**, 5, 95		999
454	Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. *Journal of Clinical Oncology*, **2006**, 24, 25-35	2.2	958
453	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. *Lancet, The*, **2015**, 386, 444-51	40	926
452	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. *New England Journal of Medicine*, **2018**, 378, 1789-1801	59.2	918
451	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. *New England Journal of Medicine*, **2016**, 375, 1845-1855	59.2	870
450	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. *Lancet Oncology, The*, **2015**, 16, 522-30	21.7	842
449	Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. *New England Journal of Medicine*, **2017**, 377, 1813-1823	59.2	778
448	Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. *Journal of Translational Medicine*, **2005**, 3, 10	8.5	769
447	Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. *Lancet Oncology, The*, **2014**, 15, 323-32	21.7	753
446	Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. *Lancet Oncology, The*, **2012**, 13, 1087-95	21.7	708
445	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). *Lancet, The*, **2017**, 390, 1853-1862	40	703
444	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. *Journal of Clinical Oncology*, **2017**, 35, 785-792	2.2	696
443	CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. *Journal of Experimental Medicine*, **2005**, 202, 1075-85	16.6	687
442	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. *JAMA - Journal of the American Medical Association*, **2016**, 315, 1600-9	27.4	666
441	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. *Lancet Oncology, The*, **2016**, 17, 1558-1568	21.7	627
440	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. *Nature Reviews Clinical Oncology*, **2016**, 13, 473-86	19.4	591
439	Electrochemotherapy An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. *European Journal of Cancer, Supplement*, **2006**, 4, 3-13	1.6	569
438	Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. *Annals of Oncology*, **2017**, 28, 1368-1379	10.3	551

437	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. *Nature*, **2014**, 508, 118-22	50.4	550
436	Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. *Annals of Oncology*, **2016**, 27, 559-74	10.3	548
435	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. *Journal of Clinical Oncology*, **2016**, 34, 1510-7	2.2	509
434	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. *New England Journal of Medicine*, **2019**, 381, 626-636	59.2	489
433	CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. *Clinical Cancer Research*, **2013**, 19, 5300-9	12.9	485
432	Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. *Journal of Clinical Oncology*, **2009**, 27, 2823-30	2.2	456
431	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncology, The*, **2018**, 19, 603-615	21.7	451
430	Cutaneous side-effects of kinase inhibitors and blocking antibodies. *Lancet Oncology, The*, **2005**, 6, 491-500	21.7	429
429	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. *Lancet Oncology, The*, **2019**, 20, 1239-1251	21.7	425
428	Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. *JAMA Dermatology*, **2016**, 152, 45-51	5.1	414
427	Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. *Journal of Clinical Oncology*, **2016**, 34, 4102-4109	2.2	400
426	Dabrafenib plus trametinib in patients with BRAF-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. *Lancet Oncology, The*, **2017**, 18, 863-873	21.7	389
425	Inflammatory skin diseases, T cells, and immune surveillance. *New England Journal of Medicine*, **1999**, 341, 1817-28	59.2	388
424	Cutaneous melanoma. *Lancet, The*, **2014**, 383, 816-27	40	379
423	A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. *Nature*, **2011**, 480, 94-8	50.4	365
422	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. *Annals of Oncology*, **2017**, 28, 1631-1639	10.3	361
421	Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. *Lancet Oncology, The*, **2019**, 20, 1083-1097	21.7	356
420	The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. *PLoS ONE*, **2013**, 8, e53745	3.7	343

419	Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. *Journal of Clinical Oncology*, **2015**, 33, 1191-6	2.2	334
418	Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. *Annals of Oncology*, **2019**, 30, 582-588	10.3	325
417	RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. *Journal of Clinical Oncology*, **2012**, 30, 316-21	2.2	318
416	Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology. *Annals of Oncology*, **2017**, 28, 1191-1206	10.3	314
415	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. *Lancet Oncology, The*, **2017**, 18, 611-622	21.7	306
414	Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncology, The*, **2018**, 19, 1315-1327	21.7	291
413	A decade of immune-checkpoint inhibitors in cancer therapy. *Nature Communications*, **2020**, 11, 3801	17.4	289
412	Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. *PLoS ONE*, **2009**, 4, e4942	3.7	286
411	Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. *Oncologist*, **2008**, 13, 1001-11	5.7	273
410	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. *Journal of Clinical Oncology*, **2017**, 35, 3807-3814	2.2	264
409	MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. *Journal of Immunology*, **2001**, 166, 3266-76	5.3	247
408	Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. *Annals of Oncology*, **2007**, 18, 2030-6	10.3	242
407	Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. *Clinical Cancer Research*, **2012**, 18, 555-67	12.9	238
406	eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. *Nature*, **2014**, 513, 105-9	50.4	237
405	Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. *Annals of Oncology*, **2013**, 24, 1697-703	10.3	237
404	Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. *Annals of Oncology*, **2020**, 31, 961-964	10.3	222
403	Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. *Journal of Hepatology*, **2018**, 68, 1181-1190	13.4	222
402	Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. *Journal of Clinical Investigation*, **2004**, 114, 379-88	15.9	218

401	Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. *Annals of the New York Academy of Sciences*, **2013**, 1291, 1-13	6.5	215
400	Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. *Journal of Clinical Oncology*, **2018**, 36, 1668-1674	2.2	210
399	Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. *Lancet Oncology, The*, **2016**, 17, 1743-1754	21.7	205
398	Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet, The*, **2020**, 395, 1835-1844	40	204
397	Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. *Journal of Clinical Oncology*, **2012**, 30, 3810-8	2.2	204
396	Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. *Clinical Cancer Research*, **2010**, 16, 1042-8	12.9	201
395	Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. *Journal of Crohn's and Colitis*, **2016**, 10, 395-401	1.5	184
394	Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. *European Journal of Cancer*, **2017**, 83, 247-257	7.5	181
393	Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. *Clinical Cancer Research*, **2017**, 23, 1929-1936	12.9	181
392	Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. *Cancer Treatment Reviews*, **2017**, 58, 70-76	14.4	173
391	Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. *JAMA Oncology*, **2019**, 5, 187-194	13.4	173
390	Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. *Archives of Dermatology*, **2008**, 144, 886-92		170
389	Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). *Genes and Development*, **2011**, 25, 1245-61	12.6	168
388	Targeted therapies for renal cell carcinoma: review of adverse event management strategies. *Journal of the National Cancer Institute*, **2012**, 104, 93-113	9.7	168
387	Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. *Archives of Dermatology*, **2007**, 143, 1144-50		168
386	Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. *Journal of Clinical Oncology*, **2011**, 29, 2206-14	2.2	164
385	Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. *Journal of Clinical Oncology*, **2013**, 31, 2413-20	2.2	163
384	Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. *Lancet Oncology, The*, **2015**, 16, 1389-98	21.7	162

383	Analysis of dermatologic events in vemurafenib-treated patients with melanoma. *Oncologist*, **2013**, 18, 314-22	5.7	162
382	Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. *Cancer Research*, **2009**, 69, 3563-9	10.1	160
381	Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. *European Journal of Cancer*, **2018**, 91, 21-29	7.5	158
380	Interaction of dendritic cells with skin endothelium: A new perspective on immunosurveillance. *Journal of Experimental Medicine*, **1999**, 189, 627-36	16.6	158
379	Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). *European Journal of Cancer*, **2011**, 47, 1476-83	7.5	157
378	Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. *Annals of Oncology*, **2008**, 19, 142-9	10.3	153
377	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Oncology*, **2020**, 6, 519-527	13.4	148
376	Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. *European Journal of Cancer*, **2012**, 48, 218-25	7.5	146
375	New drugs in melanoma: it's a whole new world. *European Journal of Cancer*, **2011**, 47, 2150-7	7.5	145
374	Interleukin-1 and cutaneous inflammation: a crucial link between innate and acquired immunity. *Journal of Investigative Dermatology*, **2000**, 114, 602-8	4.3	144
373	Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. *Oncology*, **2009**, 77, 257-71	3.6	143
372	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. *Clinical Cancer Research*, **2018**, 24, 4960-4967	12.9	142
371	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected V600-Mutant Stage III Melanoma. *Journal of Clinical Oncology*, **2018**, 36, 3441-3449	2.2	137
370	Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. *Journal of Clinical Oncology*, **2019**, 37, 867-875	2.2	135
369	Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. *Lancet Oncology, The*, **2013**, 14, 733-40	21.7	135
368	Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. *Annals of Oncology*, **2013**, 24, 1691-7	10.3	135
367	Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. *Annals of Oncology*, **2017**, 28, 2581-2587	10.3	129
366	Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. *Journal of Clinical Oncology*, **2009**, 27, e59-61	2.2	128

365	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. *Cell Research*, **2015**, 25, 208-24	24.7	126
364	Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. *Nephrology Dialysis Transplantation*, **2009**, 24, 682-5	4.3	125
363	Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. *Clinical Cancer Research*, **2007**, 13, 1801-9	12.9	124
362	Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. *Annals of Surgical Oncology*, **2006**, 13, 1596-603	3.1	124
361	Kidney injuries related to ipilimumab. *Investigational New Drugs*, **2014**, 32, 769-73	4.3	118
360	Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. *Clinical Cancer Research*, **2013**, 19, 2232-9	12.9	117
359	Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study. *Arthritis and Rheumatology*, **2019**, 71, 2100-2111	9.5	116
358	Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E9271-E9279	11.5	115
357	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. *European Journal of Cancer*, **2016**, 53, 125-34	7.5	115
356	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. *European Journal of Cancer*, **2017**, 82, 45-55	7.5	114
355	Dermatologic symptoms associated with the multikinase inhibitor sorafenib. *Journal of the American Academy of Dermatology*, **2009**, 60, 299-305	4.5	114
354	Cyclophosphamide induces differentiation of Th17 cells in cancer patients. *Cancer Research*, **2011**, 71, 661-5	10.1	113
353	Prevalence of immune-related systemic adverse events in´patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. *European Journal of Cancer*, **2017**, 82, 34-44	7.5	110
352	Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance. *Cancer Cell*, **2016**, 29, 805-819	24.3	110
351	Nail toxicities induced by systemic anticancer treatments. *Lancet Oncology, The*, **2015**, 16, e181-9	21.7	109
350	Enterocolitis due to immune checkpoint inhibitors: a systematic review. *Gut*, **2018**, 67, 2056-2067	19.2	109
349	Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. *Lancet Haematology,the*, **2019**, 6, e48-e57	14.6	109
348	Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma. *Nature Medicine*, **2018**, 24, 1877-1886	50.5	109

347	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. *European Journal of Cancer*, **2017**, 86, 37-45	7.5	106
346	Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. *New England Journal of Medicine*, **2020**, 383, 1139-1148	59.2	105
345	Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. *Clinical Cancer Research*, **2012**, 18, 263-72	12.9	103
344	Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic -Mutant Melanoma. *Clinical Cancer Research*, **2017**, 23, 5339-5348	12.9	101
343	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. *JAMA Oncology*, **2017**, 3, 1511-1519	13.4	101
342	Prognostic factors of paraneoplastic pemphigus. *Archives of Dermatology*, **2012**, 148, 1165-72		99
341	Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better?. *Annals of Oncology*, **2005**, 16, 1061-8	10.3	97
340	Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. *Nature Communications*, **2020**, 11, 2168	17.4	95
339	Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. *British Journal of Dermatology*, **2009**, 161, 515-21	4	94
338	Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.. *Journal of Clinical Oncology*, **2015**, 33, 3003-3003	2.2	94
337	Immune Checkpoint Inhibitors. *Progress in Tumor Research*, **2015**, 42, 55-66		93
336	Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?. *Clinical Cancer Research*, **2008**, 14, 5242-9	12.9	91
335	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. *Lancet Oncology, The*, **2019**, 20, e378-e389	21.7	88
334	Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). *Annals of Oncology*, **2018**, 29, 2163-2174	10.3	88
333	Cell survival and shuttle vector mutagenesis induced by ultraviolet A and ultraviolet B radiation in a human cell line. *Journal of Investigative Dermatology*, **1996**, 106, 721-8	4.3	86
332	AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study. *Journal of Clinical Oncology*, **2008**, 26, 9033-9033	2.2	86
331	Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. *Cancer Research*, **2004**, 64, 2192-8	10.1	85
330	Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). *Oncologist*, **2009**, 14, 291-302	5.7	84

329	What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?. *Oncologist*, **2009**, 14, 848-61	5.7	83
328	Systemic Therapy for Melanoma: ASCO Guideline. *Journal of Clinical Oncology*, **2020**, 38, 3947-3970	2.2	82
327	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. *European Journal of Cancer*, **2019**, 119, 1-10	7.5	79
326	Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities. *Journal of Crohn's and Colitis*, **2017**, 11, 1238-1246	1.5	79
325	Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. *Journal of Clinical Oncology*, **2013**, 31, 1211-8	2.2	78
324	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. *Journal of Clinical Oncology*, **2020**, 38, 3925-3936	2.2	78
323	Genetic variability and integration of Merkel cell polyomavirus in Merkel cell carcinoma. *Virology*, **2012**, 426, 134-42	3.6	76
322	Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. *European Journal of Cancer*, **2020**, 126, 33-44	7.5	74
321	Immature mouse dendritic cells enter inflamed tissue, a process that requires E- and P-selectin, but not P-selectin glycoprotein ligand 1. *Blood*, **2002**, 99, 946-56	2.2	72
320	Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. *Annals of Oncology*, **2017**, 28, 2860-2865	10.3	71
319	Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. *European Journal of Cancer*, **2013**, 49, 2968-71	7.5	70
318	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. *Lancet Oncology, The*, **2017**, 18, 393-403	21.7	69
317	Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. *Annals of Oncology*, **2016**, 27, 214-24	10.3	67
316	Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study. *Annals of Oncology*, **2016**, 27, 1940-6	10.3	67
315	Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. *Clinical Cancer Research*, **2019**, 25, 946-956	12.9	67
314	Vemurafenib and radiosensitization. *JAMA Dermatology*, **2013**, 149, 855-7	5.1	66
313	Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.. *Journal of Clinical Oncology*, **2016**, 34, 9503-9503	2.2	66
312	Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma.. *Journal of Clinical Oncology*, **2012**, 30, 8502-8502	2.2	65

311	Melanoma-associated fibroblasts decrease tumor cell susceptibility to NK cell-mediated killing through matrix-metalloproteinases secretion. *Oncotarget*, **2017**, 8, 19780-19794	3.3	63
310	Small molecules and targeted therapies in distant metastatic disease. *Annals of Oncology*, **2009**, 20 Suppl 6, vi35-40	10.3	61
309	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. *European Journal of Cancer*, **2015**, 51, 833-40	7.5	60
308	4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.. *Journal of Clinical Oncology*, **2018**, 36, 9503-9503	2.2	60
307	Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. *British Journal of Cancer*, **2018**, 119, 670-674	8.7	60
306	Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. *European Journal of Cancer*, **2018**, 101, 236-243	7.5	59
305	Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. *Clinical Cancer Research*, **2007**, 13, 3825-30	12.9	59
304	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. *Lancet Oncology, The*, **2021**, 22, 643-654	21.7	58
303	Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies. *Seminars in Oncology*, **2015**, 42, 429-35	5.5	57
302	Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis.. *Journal of Clinical Oncology*, **2015**, 33, 9018-9018	2.2	56
301	Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 2298-2310	8.8	55
300	Severe meningo-radiculo-neuritis associated with ipilimumab. *Investigational New Drugs*, **2012**, 30, 2407-10	4.9	55
299	Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. *Journal of Immunotherapy*, **2008**, 31, 101-12	5	54
298	Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. *European Journal of Cancer*, **2016**, 67, 46-54	7.5	54
297	The new era of adjuvant therapies for melanoma. *Nature Reviews Clinical Oncology*, **2018**, 15, 535-536	19.4	54
296	Gene electrotransfer of plasmid antiangiogenic metargidin peptide (AMEP) in disseminated melanoma: safety and efficacy results of a phase I first-in-man study. *Human Gene Therapy Clinical Development*, **2013**, 24, 99-107	3.2	51
295	ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway. *Cancer Research*, **2008**, 68, 9854-64	10.1	51
294	Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses. *Cancer Immunology, Immunotherapy*, **2008**, 57, 1291-300	7.4	51

293	Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations. *European Journal of Cancer*, **2018**, 96, 25-33	7.5	50
292	Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?. *Annals of Internal Medicine*, **2005**, 143, 313-4	8	50
291	Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. *European Journal of Cancer*, **2017**, 86, 115-124	7.5	49
290	A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. *Annals of Oncology*, **2015**, 26, 2267-74	10.3	49
289	Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. *Lancet Oncology, The*, **2014**, 15, 297-304	21.7	49
288	Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. *Lancet Oncology, The*, **2020**, 21, 358-372	21.7	49
287	ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. *Annals of Oncology*, **2020**, 31, 1435-1448	10.3	49
286	Hypopigmented mycosis fungoides. *Archives of Dermatology*, **1994**, 130, 476-480		49
285	New Functional Signatures for Understanding Melanoma Biology from Tumor Cell Lineage-Specific Analysis. *Cell Reports*, **2015**, 13, 840-853	10.6	48
284	Molecular Pathways: The eIF4F Translation Initiation Complex-New Opportunities for Cancer Treatment. *Clinical Cancer Research*, **2017**, 23, 21-25	12.9	48
283	Renal effects of immune checkpoint inhibitors. *Nephrology Dialysis Transplantation*, **2017**, 32, 936-942	4.3	48
282	Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas. *British Journal of Dermatology*, **2015** , 173, 527-34	4	47
281	Persistent Cancer Cells: The Deadly Survivors. *Cell*, **2020**, 183, 860-874	56.2	47
280	Two cases of immune thrombocytopenia associated with pembrolizumab. *European Journal of Cancer*, **2016**, 54, 172-174	7.5	47
279	Targeted therapy-induced radiation recall. *European Journal of Cancer*, **2013**, 49, 1662-8	7.5	45
278	Neutrophils, monocytes, and dendritic cells express the same specialized form of PSGL-1 as do skin-homing memory T cells: cutaneous lymphocyte antigen. *Biochemical and Biophysical Research Communications*, **2001**, 285, 577-87	3.4	45
277	3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. *European Journal of Cancer*, **2015**, 51, S663	7.5	44
276	Deleterious effects of ultraviolet A radiation in human cells. *Mutation Research DNA Repair*, **1997**, 383, 1-8		43

275	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. *European Journal of Cancer*, **2019**, 116, 148-157	7.5	42
274	A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. *Archives of Dermatology*, **2012**, 148, 1418-20		42
273	Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. *Archives of Dermatology*, **1997**, 133, 867-871		42
272	Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas. *Molecular Oncology*, **2008**, 1, 425-30	7.9	41
271	Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032- 18031). *Journal of Clinical Oncology*, **2008**, 26, 9065-9065	2.2	41
270	Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. *Nature Medicine*, **2020**, 26, 1557-1563	50.5	41
269	Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. *Advances in Therapy*, **2013**, 30, 945-66	4.1	40
268	Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. *Annals of Oncology*, **2014**, 25, 700-706	10.3	40
267	Management and outcome of metastatic melanoma during pregnancy. *British Journal of Dermatology*, **2010**, 162, 274-81	4	40
266	Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.. *Journal of Clinical Oncology*, **2015**, 33, 9005-9005	2.2	40
265	Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.. *Journal of Clinical Oncology*, **2017**, 35, 9504-9504	2.2	40
264	Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. *Lancet Oncology, The*, **2021**, 22, 848-857	21.7	40
263	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. *European Journal of Cancer*, **2020**, 130, 126-138	7.5	39
262	Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases. *Melanoma Research*, **2018**, 28, 111-119	3.3	39
261	Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. *British Journal of Cancer*, **2011**, 105, 353-9	8.7	39
260	Five-Year Outcomes With Nivolumab in Patients With Wild-Type Advanced Melanoma. *Journal of Clinical Oncology*, **2020**, 38, 3937-3946	2.2	39
259	Rapid and objective CT scan prognostic scoring identifies´metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy. *European Journal of Cancer*, **2016**, 65, 33-42	7.5	39
258	Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. *Journal of Clinical Oncology*, **2007**, 25, 8510-8510	2.2	38

257	Mast cell sarcoma: a rare and aggressive entity--report of two cases and review of the literature. *Journal of Clinical Oncology*, **2013**, 31, e90-7	2.2	37
256	Tyrosine kinase inhibition and grey hair. *Lancet, The*, **2003**, 361, 1056	40	36
255	LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600Emutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial. *Annals of Oncology*, **2020**, 31, S1172	10.3	36
254	Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?. *Current Opinion in Oncology*, **2012**, 24, 137-40	4.2	35
253	Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors. *OncoImmunology*, **2014**, 3, e27560	7.2	34
252	Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15R and NKG2D triggering. *Cancer Research*, **2014**, 74, 68-80	10.1	33
251	Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. *The Journal of Supportive Oncology*, **2011**, 9, 13-23		33
250	Anti-CTLA-4 antibody adjuvant therapy in melanoma. *Seminars in Oncology*, **2010**, 37, 455-9	5.5	33
249	Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization. *Cancer Research*, **2016**, 76, 1476-84	10.1	32
248	P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. *European Journal of Cancer*, **2017**, 83, 154-165	7.5	32
247	Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety. *Annals of Oncology*, **2012**, 23, 1301-1306	10.3	32
246	Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006.. *Journal of Clinical Oncology*, **2016**, 34, 9504-9504	2.2	32
245	Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 2301-2312	8.8	31
244	Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1. *Annals of the Rheumatic Diseases*, **2019**, 78, e67	2.4	31
243	Advances in the management of cutaneous toxicities of targeted therapies. *Seminars in Oncology*, **2012**, 39, 227-40	5.5	31
242	Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma. *Journal of the European Academy of Dermatology and Venereology*, **2010**, 24, 199-203	4.6	31
241	Introduction of functional chimeric E/L-selectin by RNA electroporation to target dendritic cells from blood to lymph nodes. *Cancer Immunology, Immunotherapy*, **2008**, 57, 467-77	7.4	31
240	Prevalence of sunbed use, and characteristics and knowledge of sunbed users: results from the French population-based Edifice Melanoma survey. *Journal of the European Academy of Dermatology and Venereology*, **2015**, 29 Suppl 2, 23-30	4.6	30

239	Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. *European Journal of Cancer*, **2019**, 106, 106-114	7.5	30
238	Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey. *ESMO Open*, **2018**, 3, e000422	6	30
237	A case of Rothmund-Thomson syndrome with reduced DNA repair capacity. *Archives of Dermatology*, **1993**, 129, 332-336		30
236	Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma. *Cancer Immunology, Immunotherapy*, **2019**, 68, 1171-1178	7.4	28
235	Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm. *Nature Reviews Clinical Oncology*, **2020**, 17, 707-715	19.4	28
234	Correlation of phenotype/genotype in a cohort of 23 xeroderma pigmentosum-variant patients reveals 12 new disease-causing POLH mutations. *Human Mutation*, **2014**, 35, 117-28	4.7	28
233	Bullous Amyloidosis. *Medicine (United States)*, **1993**, 72, 38-44	1.8	28
232	An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells. *Nature Communications*, **2019**, 10, 5713	17.4	28
231	New Era in the Management of Melanoma Brain Metastases. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2018**, 38, 741-750	7.1	28
230	Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. *European Journal of Cancer*, **2019**, 119, 97-106	7.5	27
229	Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting. *Current Opinion in Oncology*, **2020**, 32, 106-113	4.2	27
228	Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. *JAMA Oncology*, **2020**, 6, 1256-1264	13.4	27
227	Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K mutant cutaneous melanoma. *Annals of Oncology*, **2016**, 27, vi575	10.3	26
226	Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors. *Cancer Research*, **2014**, 74, 2238-45	10.1	26
225	The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600 mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.. *Journal of Clinical Oncology*, **2019**, 37, 9531-9531	2.2	26
224	Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. *Clinical Cancer Research*, **2020**, 26, 4201-4205	12.9	25
223	Gap junction communication between autologous endothelial and tumor cells induce cross-recognition and elimination by specific CTL. *Journal of Immunology*, **2009**, 182, 2654-64	5.3	25
222	Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial. *Journal of the American Academy of Dermatology*, **2016**, 74, 1077-85	4.5	24

221	Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR NK cell levels correlate with disease outcome. *OncoImmunology*, **2013**, 2, e23080	7.2	24
220	5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.. *Journal of Clinical Oncology*, **2018**, 36, 9516-9516	2.2	24
219	Genomic Features of Exceptional Response in Vemurafenib – Cobimetinib-treated Patients with -mutated Metastatic Melanoma. *Clinical Cancer Research*, **2019**, 25, 3239-3246	12.9	23
218	Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF or BRAF mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. *Lancet Oncology, The*, **2019**, 20, 701-710	21.7	23
217	Severe cutaneous adverse reaction associated with vemurafenib: DRESS, AGEP or overlap reaction?. *Journal of the European Academy of Dermatology and Venereology*, **2016**, 30, 178-9	4.6	23
216	Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study. *Cancer Immunology, Immunotherapy*, **2018**, 67, 1571-1578	7.4	23
215	KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. *Future Oncology*, **2020**, 16, 4429-4438	3.6	23
214	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. *European Journal of Cancer*, **2021**, 144, 182-191	7.5	23
213	Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. *European Journal of Cancer*, **2018**, 91, 168-170	7.5	23
212	Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone. *Annals of Oncology*, **2017**, 28, v428	10.3	22
211	Adjuvant Pembrolizumab in Resected Stage III Melanoma. *New England Journal of Medicine*, **2018**, 379, 593-595	59.2	22
210	Update on the role of ipilimumab in melanoma and first data on new combination therapies. *Current Opinion in Oncology*, **2013**, 25, 166-72	4.2	22
209	Gene therapy to target dendritic cells from blood to lymph nodes. *Gene Therapy*, **2003**, 10, 1479-86	4	22
208	Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma. *European Journal of Cancer*, **2015**, 51, 1780-93	7.5	21
207	Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors. *Community Oncology*, **2010**, 7, 23-29		21
206	Thyroid adenomas and carcinomas following radiotherapy for a hemangioma during infancy. *Radiotherapy and Oncology*, **2009**, 93, 377-82	5.3	21
205	Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. *Lancet Oncology, The*, **2021**, 22, 370-380	21.7	21
204	The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients - An EORTC Melanoma Group study. *European Journal of Surgical Oncology*, **2016**, 42, 1906-1913	3.6	21

203	Is earlier better for melanoma checkpoint blockade?. *Nature Medicine*, **2018**, 24, 1645-1648	50.5	21
202	A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma. *Journal of Translational Medicine*, **2015**, 13, O5	8.5	20
201	Arterial thrombosis and anti-PD-1 blockade. *European Journal of Cancer*, **2018**, 91, 164-166	7.5	20
200	Melanoma in 2011: a new paradigm tumor for drug development. *Nature Reviews Clinical Oncology*, **2012**, 9, 74-6	19.4	20
199	Malignant melanoma and granulomatosis. *British Journal of Dermatology*, **1997**, 137, 787-792	4	20
198	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. *Nature Communications*, **2020**, 11, 6262	17.4	20
197	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition **2021**, 9,		20
196	Familial predisposition to TP53/complex karyotype MDS and leukemia in DNA repair-deficient xeroderma pigmentosum. *Blood*, **2019**, 133, 2718-2724	2.2	19
195	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma **2020**, 8,		19
194	Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab. *European Journal of Cancer*, **2018**, 91, 171-173	7.5	19
193	Melanoma Persister Cells Are Tolerant to BRAF/MEK Inhibitors via ACOX1-Mediated Fatty Acid Oxidation. *Cell Reports*, **2020**, 33, 108421	10.6	19
192	ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. *Annals of Oncology*, **2020**, 31, 1449-1461	10.3	19
191	Intratumoral Immunotherapy: From Trial Design to Clinical Practice. *Clinical Cancer Research*, **2021**, 27, 665-679	12.9	19
190	Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600´E/K-mutant advanced or metastatic melanoma. *European Journal of Cancer*, **2019**, 109, 61-69	7.5	18
189	Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).. *Journal of Clinical Oncology*, **2014**, 32, LBA9000-LBA9000	2.2	18
188	Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3. *Oncotarget*, **2017**, 8, 108786-108801	3.3	18
187	Immune Checkpoint Inhibitor Therapy Aggravates T Cell-Driven Plaque Inflammation in Atherosclerosis. *JACC: CardioOncology*, **2020**, 2, 599-610	3.8	18
186	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.. *Lancet, The*, **2022**,	40	18

185	The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. *European Journal of Cancer*, **2020**, 130, 39-50	7.5	17
184	Mechanisms of skin aging induced by EGFR inhibitors. *Supportive Care in Cancer*, **2016**, 24, 4241-8	3.9	17
183	Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.. *Journal of Clinical Oncology*, **2014**, 32, 3015-3015	2.2	17
182	Tumour burden and efficacy of immune-checkpoint inhibitors. *Nature Reviews Clinical Oncology*, **2021**,	19.4	17
181	Cutaneous malignant melanoma in children and adolescents treated in pediatric oncology units. *Pediatric Blood and Cancer*, **2016**, 63, 1922-7	3	17
180	Report on the status of women occupying leadership roles in oncology. *ESMO Open*, **2018**, 3, e000423	6	17
179	Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?. *Seminars in Immunopathology*, **2017**, 39, 327-331	12	16
178	Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate. *OncoImmunology*, **2013**, 2, e23079	7.2	16
177	BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets).. *Journal of Clinical Oncology*, **2012**, 30, 8501-8501	2.2	16
176	Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site. *Annals of Surgical Oncology*, **2014**, 21, 4317-23	3.1	15
175	Acute Lower Limb Ischaemia and Diabetes in a Patient Treated with Anti-PD1 Monoclonal Antibody for Metastatic Melanoma. *Acta Dermato-Venereologica*, **2017**, 97, 408-409	2.2	15
174	Pembrolizumab (Pembro; Mk-3475) for Advanced Melanoma (Mel): Randomized Comparison of Two Dosing Schedules. *Annals of Oncology*, **2014**, 25, v1	10.3	15
173	The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave Roussy. *Molecular Oncology*, **2012**, 6, 204-10	7.9	15
172	A prospective coagulation study including resistance to activated protein C and mutations in factors V and II in venous leg ulcers. *British Journal of Dermatology*, **1999**, 141, 259-63	4	15
171	Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.. *Journal of Clinical Oncology*, **2020**, 38, 10000-10000	2.2	15
170	Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review. *JAMA Oncology*, **2020**, 6, 1957-1966	13.4	15
169	Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives. *British Journal of Cancer*, **2020**, 123, 885-897	8.7	15
168	Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. *Cancer Chemotherapy and Pharmacology*, **2011**, 68, 53-61	3.5	14

167	Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study.. *Journal of Clinical Oncology*, **2015**, 33, 9004-9004	2.2	14
166	Loss of Ambra1 promotes melanoma growth and invasion. *Nature Communications*, **2021**, 12, 2550	17.4	14
165	Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.. *Journal of Clinical Oncology*, **2014**, 32, LBA9008-LBA9008	2.2	13
164	Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.. *Journal of Clinical Oncology*, **2019**, 37, 2512-2512	2.2	13
163	Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study. *Oncotarget*, **2020**, 11, 378-385	3.3	13
162	Pregnancy and melanoma: a European-wide survey to assess current management and a critical literature overview. *Journal of the European Academy of Dermatology and Venereology*, **2017**, 31, 65-69	4.6	12
161	Adverse events 2.0-Let us get SERIOs: New reporting for´adverse event outcomes needed in the era of immunooncology. *European Journal of Cancer*, **2019**, 112, 29-31	7.5	12
160	Who benefits most from adjuvant interferon treatment for melanoma?. *American Journal of Therapeutics*, **2015**, 22, 54-60	1	12
159	Risk-based stratification in head and neck mucosal melanoma. *Oral Oncology*, **2019**, 97, 44-49	4.4	12
158	A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. *Journal of Clinical Oncology*, **2008**, 26, 9023-9023	2.2	12
157	Pimasertib Versus Dacarbazine in Patients With Unresectable -Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. *Cancers*, **2020**, 12,	6.6	12
156	Sentinel lymph node biopsy in cutaneous head and neck melanoma. *European Archives of Oto-Rhino-Laryngology*, **2018**, 275, 1271-1279	3.5	11
155	PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis. *Annals of Oncology*, **2016**, 27, vi381	10.3	11
154	Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature. *ESMO Open*, **2017**, 2, e000203	6	11
153	Comparison of sun protection modalities in parents and children. *Journal of the European Academy of Dermatology and Venereology*, **2015**, 29 Suppl 2, 16-9	4.6	11
152	Successful repetitive treatments by electrochemotherapy of multiple unresectable Kaposi sarcoma nodules. *European Journal of Cancer, Supplement*, **2006**, 4, 29-31	1.6	11
151	Hypopigmented mycosis fungoides in a light-skinned woman. *British Journal of Dermatology*, **1998**, 139, 341-3	4	11
150	Redox activation of ATM enhances GSNOR translation to sustain mitophagy and tolerance to oxidative stress. *EMBO Reports*, **2021**, 22, e50500	6.5	11

149	The plasticity of mRNA translation during cancer progression and therapy resistance. *Nature Reviews Cancer*, **2021**, 21, 558-577	31.3	11
148	The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. *European Journal of Cancer*, **2021**, 155, 268-280	7.5	11
147	Sun exposure profile in the French population. Results of the EDIFICE Melanoma survey. *Journal of the European Academy of Dermatology and Venereology*, **2015**, 29 Suppl 2, 6-10	4.6	10
146	Longitudinal subungual acanthoma: one denomination for various clinical presentations. *Journal of the European Academy of Dermatology and Venereology*, **2018**, 32, 1608-1613	4.6	10
145	P315 Gastrointestinal immune related adverse events associated with programmed-Death 1 blockade. *Journal of Crohnks and Colitis*, **2017**, 11, S237-S237	1.5	10
144	HIV-negative patient with HHV-8 DNA follicular B-cell lymphoma associated with Kaposi© sarcoma. *Lancet, The*, **1996**, 347, 1042-3	40	10
143	Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for V600-Mutant Unresectable or Metastatic Melanoma.. *Journal of Clinical Oncology*, **2022**, JCO2101601	2.2	10
142	Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.. *Journal of Clinical Oncology*, **2020**, 38, 10012-10012	2.2	10
141	Immature mouse dendritic cells enter inflamed tissue, a process that requires E- and P-selectin, but not P-selectin glycoprotein ligand 1. *Blood*, **2002**, 99, 946-956	2.2	10
140	The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV-UEMS and EORTC Cutaneous Lymphoma Task Force. *Journal of the European Academy of Dermatology and Venereology*, **2020**, 34, 2183-2197	4.6	10
139	The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study. *Melanoma Research*, **2018**, 28, 333-340	3.3	10
138	Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma. *Journal of Translational Medicine*, **2015**, 13, O6	8.5	9
137	Treatment algorithms in stage IV melanoma. *American Journal of Therapeutics*, **2015**, 22, 61-7	1	9
136	Expanded access programmes: patient interests versus clinical trial integrity. *Lancet Oncology, The*, **2015**, 16, 15-7	21.7	9
135	Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy.. *Cancer Cell*, **2022**,	24.3	9
134	Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL).. *Journal of Clinical Oncology*, **2014**, 32, 3000-3000	2.2	9
133	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. *Lancet Oncology, The*, **2021**, 22, 655-664	21.7	9
132	Impact of dermatologic adverse events induced by targeted therapies on quality of life. *Critical Reviews in Oncology/Hematology*, **2016**, 101, 158-68	7	9

131	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. *British Journal of Cancer*, **2021**, 124, 574-580	8.7	9
130	Interventional Radiology for Local Immunotherapy in Oncology. *Clinical Cancer Research*, **2021**, 27, 2698-2705	12.5	9
129	Melanoma during fingolimod treatment for multiple sclerosis. *European Journal of Cancer*, **2019**, 113, 75-77	7.5	8
128	Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial. *European Journal of Cancer*, **2020**, 133, 94-103	7.5	8
127	Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines. *Cell Cycle*, **2016**, 15, 2405-9	4.7	8
126	Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. *Journal of Translational Medicine*, **2016**, 14, 65	8.5	8
125	One or Two Immune Checkpoint Inhibitors?. *Cancer Cell*, **2019**, 36, 579-581	24.3	8
124	Impact of COVID-19 on healthcare organisation and cancer outcomes. *European Journal of Cancer*, **2021**, 153, 123-132	7.5	8
123	Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. *Annals of Oncology*, **2021**, 32, 1381-1390	10.3	8
122	Side effects and toxicities of targeted therapies in stage IV melanoma. *American Journal of Therapeutics*, **2015**, 22, 44-53	1	7
121	Checkpoint Blockade Plus Oncolytic Virus: A Hot Therapeutic Cancer Strategy. *Trends in Molecular Medicine*, **2017**, 23, 983-985	11.5	7
120	Evolution of sun-protection measures for children. *Journal of the European Academy of Dermatology and Venereology*, **2015**, 29 Suppl 2, 20-2	4.6	7
119	Abstract CT012: Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients withBRAFV600mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trial **2020**,		7
118	Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma.. *Journal of Clinical Oncology*, **2018**, 36, 9590-9590	2.2	7
117	Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma **2020**, 8,		7
116	Asymmetric Acral Spared Phenomenon Related to Systemic Anticancer Therapies. *Skin Appendage Disorders*, **2018**, 4, 315-319	1.4	6
115	Management of Sentinel-Node Metastasis in Melanoma. *New England Journal of Medicine*, **2018**, 378, 85-88	59.2	6
114	Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples. *Investigational New Drugs*, **2014**, 32, 312-22	4.3	6

113	Regulation of gap junctions in melanoma and their impact on Melan-A/MART-1-specific CD8+ T lymphocyte emergence. *Journal of Molecular Medicine*, **2013**, 91, 1207-20	5.5	6
112	Clinical outcomes after interstitial brachytherapy for early-stage nasal squamous cell carcinoma. *Brachytherapy*, **2017**, 16, 1021-1027	2.4	6
111	EDIFICE Melanoma survey: knowledge and attitudes on melanoma prevention and diagnosis. *Journal of the European Academy of Dermatology and Venereology*, **2015**, 29 Suppl 2, 11-5	4.6	6
110	Four-Year Survival Update for Metastatic Melanoma (MM) Patients (PTS) Treated with Ipilimumab (IPI) + Dacarbazine (DTIC) on Phase 3 Study CA184-024. *Annals of Oncology*, **2012**, 23, ix367	10.3	6
109	Breast cancer following radiotherapy for a hemangioma during childhood. *Cancer Causes and Control*, **2010**, 21, 1807-16	2.8	6
108	Malignant hypercalcemia induced by a parathyroid hormone-related protein secreted by a cutaneous squamous cell carcinoma. *Archives of Dermatology*, **1997**, 133, 113		6
107	Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma.. *Journal of Clinical Oncology*, **2021**, 39, 9507-9507	2.2	6
106	Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma. *British Journal of Surgery*, **2017**, 104, 726-733	5.3	5
105	Post-shingles granulomatous dermatosis related to anti-programmed cell death 1. *Immunotherapy*, **2019**, 11, 591-598	3.8	5
104	Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer?. *European Journal of Dermatology*, **2014**, 24, 265-7	0.8	5
103	A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents. *Cancer Research*, **2017**, 77, 557-565	10.1	5
102	Systemic Therapy Options for Patients With Unresectable Melanoma. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2017**, 37, 661-672	7.1	5
101	Radiotherapy as a risk factor for malignant melanoma after childhood skin hemangioma. *Melanoma Research*, **2012**, 22, 77-85	3.3	5
100	Pooled analysis of safety over time and link between adverse events and efficacy across combination dabrafenib and trametinib (D+T) registration trials.. *Journal of Clinical Oncology*, **2016**, 34, 9534-9534	2.2	5
99	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. *European Journal of Cancer*, **2021**, 158, 156-168	7.5	5
98	Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial. *European Radiology*, **2021**, 31, 1853-1862	8	5
97	Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial. *Annals of Oncology*, **2018**, 29, viii456	10.3	5
96	Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation. *European Journal of Cancer*, **2021**, 158, 208-216	7.5	5

95	The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection. *European Journal of Cancer*, **2020**, 134, 9-18	7.5	4
94	Melanoma recurrence after adjuvant targeted therapy: A multicenter analysis.. *Journal of Clinical Oncology*, **2020**, 38, 10016-10016	2.2	4
93	Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib. *Clinical Cancer Research*, **2021**, 27, 4500-4510	12.9	4
92	Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules. *Clinical Cancer Research*, **2021**,	12.9	4
91	Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. *European Journal of Cancer*, **2021**, 153, 234-241	7.5	4
90	Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib. *European Journal of Cancer*, **2021**, 154, 57-65	7.5	4
89	Can radiation-recall predict long lasting response to immune checkpoint inhibitors?. *Radiotherapy and Oncology*, **2021**, 154, 125-127	5.3	4
88	Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. *Patient*, **2020**, 13, 457-467	3.7	3
87	Pulmonary nodules and immunotherapy: disease progression or toxicity of anti-PD1/anti-PDL1 checkpoint inhibitors?. *European Journal of Cancer*, **2018**, 93, 144-146	7.5	3
86	Melanoma risk-takers: fathers and sons. *Journal of the European Academy of Dermatology and Venereology*, **2015**, 29 Suppl 2, 35-8	4.6	3
85	Molecular pathology of cutaneous melanoma. *Melanoma Management*, **2014**, 1, 151-164	2.1	3
84	Mélanome : Thérapeutique par les médications : anticorps anti-CTLA-4 et anti-PD1. *Bulletin De L'Academie Nationale De Medecine*, **2014**, 198, 297-308	0.1	3
83	Abscopal antitumor effect in a patient with melanoma and coronavirus disease 2019. *European Journal of Cancer*, **2021**, 149, 91-93	7.5	3
82	Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop. *Clinical Cancer Research*, **2021**, 27, 394-401	12.9	3
81	The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. *Melanoma Research*, **2021**, 31, 181-185	3.3	3
80	Boosting Immunity by Targeting Post-translational Prenylation of Small GTPases. *Cell*, **2018**, 175, 901-902	36.2	3
79	Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas. *OncoImmunology*, **2019**, 8, e1660121	7.2	2
78	Sentinel lymph node biopsy in 33 non-melanoma skin cancers of the head and neck: A twelve-year experience with long-term follow-up. *Clinical Otolaryngology*, **2018**, 43, 1148-1152	1.8	2

77	Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting. *Annals of Oncology*, **2019**, 30, v543-v544	10.3	2
76	P202 Ipilimumab colitis: a GETAID multicentric study. *Journal of Crohn's and Colitis*, **2014**, 8, S146	1.5	2
75	Successful re-challenge with anti-BRAF and anti-MEK in a patient with symptomatic melanoma flare. *European Journal of Cancer*, **2017**, 82, 25-26	7.5	2
74	Personal vs. intrinsic melanoma risk awareness: results of the EDIFICE Melanoma survey. *Journal of the European Academy of Dermatology and Venereology*, **2015**, 29 Suppl 2, 31-4	4.6	2
73	Folliculitis and perionyxis associated with the EGFR inhibitor erlotinib. *Targeted Oncology*, **2006**, 1, 100-103	3	2
72	Doppler-Ultrasonography with perfusion software and contrast medium injection as an early evaluation tool of gastro intestinal stromal tumor (GIST) treated by imatinib: Results of a prospective study. *Journal of Clinical Oncology*, **2004**, 22, 9048-9048	2.2	2
71	Patient-reported outcomes (PROs) in KEYNOTE-002, a randomized study of pembrolizumab vs chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) metastatic melanoma (MEL).. *Journal of Clinical Oncology*, **2015**, 33, 9040-9040	2.2	2
70	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.. *European Journal of Cancer*, **2021**, 162, 22-33	7.5	2
69	Seminal vesicle metastasis of cutaneous malignant melanoma: An unusual and challenging presentation. *Canadian Urological Association Journal*, **2015**, 9, E220-3	1.2	2
68	Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review. *Melanoma Management*, **2019**, 6, MMT33	2.1	2
67	Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial. *Annals of Oncology*, **2018**, 29, viii446	10.3	2
66	Elevated Levels of Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma.. *JCO Precision Oncology*, **2018**, 2, 1-17	3.6	2
65	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). *European Journal of Cancer*, **2021**, 152, 116-128	7.5	2
64	Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control study. *European Journal of Cancer*, **2021**, 156, 46-59	7.5	2
63	Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities. *European Journal of Cancer*, **2021**, 157, 383-390	7.5	2
62	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. *European Journal of Cancer*, **2021**, 157, 391-402	7.5	2
61	BRAF exon 11 mutant melanoma and sensitivity to BRAF/MEK inhibition: Two case reports. *European Journal of Cancer*, **2019**, 121, 109-112	7.5	1
60	Reply to E. Hindi and K.R. Hess. *Journal of Clinical Oncology*, **2019**, 37, 1356-1358	2.2	1

59	Impact of Skin Toxicities Associated with Targeted Cancer Therapies on Body Image: A Prospective Study. *Clinical Drug Investigation*, **2016**, 36, 235-42	3.2	1
58	Metastatic melanoma: New paradigms of treatment and new toxicities. *European Journal of Cancer, Supplement*, **2013**, 11, 278-80	1.6	1
57	Bioactive Flavaglines: Synthesis and Pharmacology **2015**, 171-198		1
56	Visceral lesions occurring during follow-up of melanoma patients: a true place for other diagnosis than melanoma metastasis. *Journal of the European Academy of Dermatology and Venereology*, **2012**, 26, 602-10	4.6	1
55	Twenty-two cutaneous primary melanomas in a patient with high genetic predisposition to melanoma receiving levodopa therapy for Parkinson's disease. *Pigment Cell and Melanoma Research*, **2009**, 22, 851-3	4.5	1
54	Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-PD-1 Therapy.. *JCO Precision Oncology*, **2021**, 5,	3.6	1
53	First case of a melanocytic intrabulbar brain tumour treated with bevacizumab.. *European Journal of Cancer*, **2022**, 162, 206-208	7.5	1
52	Dermatologic Side Effects of Systemic Anticancer Therapy **2013**, 381-419		1
51	Nail Abnormalities in Oncology Practice115-121		1
50	Reply to: "Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?". *Journal of Hepatology*, **2019**, 70, 566-567	13.4	1
49	Prognostic value and therapeutic implications of nodal involvement in head and neck mucosal melanoma. *Head and Neck*, **2021**, 43, 2325-2331	4.2	1
48	Reply to: "Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study". *Journal of Hepatology*, **2018**, 69, 1397-1398	13.4	1
47	The Role of mRNA Translational Control in Tumor Immune Escape and Immunotherapy Resistance. *Cancer Research*, **2021**, 81, 5596-5604	10.1	1
46	Neurotoxicity induced by targeted therapies in patients treated for metastatic melanoma. *European Journal of Cancer*, **2019**, 111, 8-11	7.5	0
45	Estimating causal effects of time-dependent exposures on a binary endpoint in a high-dimensional setting. *BMC Medical Research Methodology*, **2018**, 18, 67	4.7	0
44	Reply to: "Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?". *Journal of Hepatology*, **2018**, 69, 550-551	13.4	0
43	Acute pancreatitis after vismodegib for basal cell carcinoma: a causal relation?. *European Journal of Cancer*, **2019**, 118, 67-69	7.5	0
42	Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus.. *European Journal of Cancer*, **2022**, 163, 79-87	7.5	0

41	Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis. *BMC Cancer*, **2021**, 21, 1244	4.8	0
40	Keratoacanthoma or cutaneous squamous cell carcinoma revealing a DNA mismatch repair default (Muir-Torre Syndrome). *Journal of the European Academy of Dermatology and Venereology*, **2022**, 36 Suppl 1, 74-76	4.6	0
39	Refractive changes during immunotherapy: Think diabetes!. *European Journal of Cancer*, **2021**, 158, 15-16	7.5	0
38	Adjuvant therapy in stage IIIA melanoma - AuthorsÕreply. *Lancet Oncology, The*, **2021**, 22, e300	21.7	0
37	Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study. *International Journal of Cancer*, **2021**, 148, 2789-2798	7.5	0
36	Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic. *ESMO Open*, **2018**, 3, e000384	6	0
35	Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?. *Annals of Oncology*, **2021**, 32, 936-937	10.3	0
34	Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Events. *JAMA Oncology*, **2021**, 7, 1573-1574	13.4	0
33	detection of the eIF4F translation initiation complex in mammalian cells and tissues. *STAR Protocols* , **2021**, 2, 100621	1.4	0
32	Troponin increase during immunotherapy: Not always myocarditis. *European Journal of Cancer*, **2021**, 157, 424-427	7.5	0
31	Prognostic and predictive value of Ebblockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.. *European Journal of Cancer*, **2022**, 165, 97-112	7.5	0
30	LAG-3 and PD-1 blockade raises the bar for melanoma.. *Nature Cancer*, **2021**, 2, 1251-1253	15.4	0
29	Mitochondrial myopathy associated with anti-programmed cell death 1 therapy. *European Journal of Cancer*, **2019**, 110, 71-73	7.5	
28	Melanoma: Immunotherapy in Advanced Melanoma and in the Adjuvant Setting **2018**, 579-591		
27	Dermatologic Side Effects of Systemic Targeted Anticancer Therapy **2018**, 285-313		
26	Reply to: "Mortality due to immunotherapy related hepatitis". *Journal of Hepatology*, **2018**, 69, 978-979	13.4	
25	MEastase sous-cutanE jugale de mElanome malin. *Annales Francaises DlOto-Rhino-Laryngologie Et De Pathologie Cervico-Faciale*, **2014**, 131, 176-178	0	
24	Hypodermal metastasis of malignant melanoma to the cheek. *European Annals of Otorhinolaryngology, Head and Neck Diseases*, **2014**, 131, 189-91	2.2	

23	Melanoma cutaneo cervicofacial. *EMC - Otorrinolaringologia*, **2017**, 46, 1-9	0
22	Melanomi cutanei cervicofacciali. *EMC - Otorinolaringoiatria*, **2017**, 16, 1-9	0
21	Development of Novel Anticancer Agents that Target Prohibitins and the Translation Initiation Factor eIF4A. *Annals of Oncology*, **2015**, 26, ii25	10.3
20	Drug-induced Nail Changes **2012**, 413-442	
19	EORTC Melanoma Group achievements. *European Journal of Cancer, Supplement*, **2012**, 10, 112-119	1.6
18	Small Molecule Multikinase Inhibitors **2013**, 196-207	
17	Comment gérer au mieux la toxicité des traitements antiangiogéniques? **2008**, 197-205	
16	Homing receptors: potential therapeutical tools?. *Experimental Dermatology*, **2002**, 11, 472-473	4
15	Multi-omics prediction in melanoma immunotherapy: A new brick in the wall.. *Cancer Cell*, **2022**, 40, 14-16	24.3
14	Discovery of Iminobenzimidazole Derivatives as Novel Cytotoxic Agents. *Open Medicinal Chemistry Journal*, **2018**, 12, 74-83	1.2
13	Dermatological Complications of Systemic Therapies for Melanoma **2019**, 1-22	
12	Management of Melanoma Brain Metastasis **2020**, 281-287	
11	Dermatological Complications of Systemic Therapies for Melanoma **2020**, 1337-1358	
10	Bariatric surgery in a patient treated with targeted therapies for metastatic melanoma: a case report. *Melanoma Research*, **2020**, 30, 629-630	3.3
9	Immune Checkpoint Inhibitors in Melanoma Define a New Era in Immunotherapy Aiming for Cure **2017**, 427-436	
8	Immunotherapy of Melanoma: A New Era **2011**, 359-372	
7	Dermatologic Manifestations of Systemic Oncologic Therapy of Cutaneous Malignancies **2011**, 379-385	
6	Molecular testing in Cutaneous Melanoma **2014**, 363-374	

5	Is it melanoma? Ask my dog!. *Melanoma Research*, **2020**, 30, 529-530	3.3
4	Reply to E. Hindi *Journal of Clinical Oncology*, **2021**, 39, 944-946	2.2
3	Combination of targeted therapy and immune checkpoint blocker in a patient with xeroderma pigmentosum presenting an aggressive angiosarcoma and a recurrent non-resectable basal cell carcinoma. *European Journal of Cancer*, **2021**, 150, 130-132	7.5
2	Anticancer Therapies **2018**, 604-616	
1	The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.. *Journal of Translational Medicine*, **2022**, 20, 200	8.5